How We’re Mobilizing Our Resources to Help Find Solutions for COVID-19
Learn More
Share
Latest News
As the European Commission grants Marketing Authorization for the company's Ebola vaccine regimen—a key step towards enabling broader access to it for the people who need it most—we share top facts about the vaccine for the deadly virus.
From scientists working on a potential vaccine to medically trained employees who mobilized to the front lines to help treat patients, these men and women share what most resonates for them about the unique and devastating virus, both professionally and personally.
Johnson & Johnson's Chief Communication Officer Michael Sneed sits down to have a frank discussion about what we need to do to help build a more equitable healthcare system—and society.
30 mothers. Their 31 children. Ten years ago, Kimberly Capone, Ph.D., set out to study the ways the microorganisms living on their skin evolved over time—and what that could mean for our understanding of skin health. She shares the groundbreaking results.
If you could help those most critically ill with the novel coronavirus, would you? Employee and trained nurse Laura Gador jumped at the chance to volunteer at a hospital in Hamburg, Germany—and is sharing her hardships and triumphs, and what's giving her strength.
Doctors, nurses and other healthcare professionals are working tirelessly to treat patients infected with the novel coronavirus. To bolster their heroic efforts, the company committed $50 million to help organizations dedicated to helping them.
Think you are up to speed on the novel coronavirus? Take this quiz to test your virus knowledge.
In light of current events taking place across the country, our Chairman and CEO sent this letter to the company's 135,000 global employees.
Imagine being a researcher who is staring down not only a highly infectious virus, but one that's caused the first global pandemic in more than 100 years. Meet Johnson & Johnson's Hanneke Schuitemaker, Ph.D.
When Melissa Surdez received an urgent call from her physician sister who was battling the pandemic on the front lines in New Jersey and facing a mask shortage, she promised to help—and tapped Johnson & Johnson's thousands of employees to join her cause.
Johnson & Johnson has an expansive archive of existing drug compounds—and two researchers are leading the charge in combing through this molecular storehouse in pursuit of a possible breakthrough.
Scientists at the facility, opening in the nation's capital this year, will be focused on advancing breakthrough ideas for safeguarding people around the world from pandemics like COVID-19, infectious diseases and other health threats.
The article explores what guided the decision, which is just the latest example of our Chairman and CEO's people-first approach to leadership at our healthcare company.
Roland Zahn, Ph.D., a Janssen scientist and expert in viral vaccines, was at the front lines of research during the Ebola outbreak. Today he and his team are working at record speed to help deliver a potential vaccine for the novel coronavirus.
Check out this infographic breakdown of the company’s first-quarter 2020 performance, with key highlights from its pharmaceutical, consumer and medical devices businesses.
